(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 9.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Vertex Pharmaceuticals's revenue in 2026 is $12,218,000,000.On average, 34 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,374,596,824,432, with the lowest VRTX revenue forecast at $3,222,313,574,232, and the highest VRTX revenue forecast at $3,491,093,510,835. On average, 33 Wall Street analysts forecast VRTX's revenue for 2027 to be $3,707,843,336,953, with the lowest VRTX revenue forecast at $3,335,510,790,214, and the highest VRTX revenue forecast at $4,317,230,143,170.
In 2028, VRTX is forecast to generate $4,119,515,723,327 in revenue, with the lowest revenue forecast at $3,533,986,626,308 and the highest revenue forecast at $4,797,429,992,134.